Home LiteratureArticle Details
PMID: 23967178 Published · epublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis.

PloS one ·Vol. 8 ·No. 8 ·2013-00-00 ·Pages e71270

Milsom CC, Lee CR, Hackl C, Man S, Kerbel RS

Abstract

We compare for the first time, the metastatic aggressiveness of the parental MDA-MB-231 breast cancer cell line and two luciferase-tagged in vivo-derived and selected pro-metastatic variants (LM2-4/luc⁺ and 164/8-1B/luc⁺ in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) (NSG) mice following orthotopic implantation and primary tumour resection. The variants are known to be more aggressively metastatic in SCID mice, compared to the parental line which has limited spontaneous metastatic competence in these mice. When 2×10⁶ cells were injected into the mammary fat pad, the growth of the resultant primary tumours was identical for the various cell lines in the three strains of mice. However, metastatic spread of all three cell lines, including the MDA-MB-231 parental cell line, was strikingly more aggressive in the highly immunocompromised NSG mice compared to both NOD-SCID and SCID mice, resulting in extensive multi-organ metastases and a significant reduction in overall survival. While these studies were facilitated by monitoring post-surgical spontaneous metastases using whole body bioluminescence imaging, we observed that the luciferase-tagged parental line showed altered growth and diminished metastatic properties compared to its untagged counterpart. Our results are the first to show that host immunity can have a profound impact on the spread of spontaneous visceral metastases and survival following resection of a primary tumour in circumstances where the growth of primary tumours is not similarly affected; as such they highlight the importance of immunity in the metastatic process, and by extension, suggest certain therapeutic strategies that may have a significant impact on reducing metastasis.

MeSH Terms
Animals Cell Line, Tumor Cell Proliferation Cell Transformation, Neoplastic Female Gene Deletion Humans Luciferases, Firefly/genetics Mammary Neoplasms, Experimental/genetics,pathology,surgery Mice Mice, Inbred NOD Mice, SCID Neoplasm Grading Neoplasm Metastasis Receptors, Interleukin-2/deficiency,genetics Survival Analysis
Chemicals
Receptors, Interleukin-2 Luciferases, Firefly
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Milsom Chloe C
Department of Medical Biophysics, University of Toronto and Biological Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada. cmilsom@sri.utoronto.ca
Lee Christina R
Hackl Christina
Man Shan
Kerbel Robert S
References (42)
42 references, click to expand
  1. SCID mouse models of human stem cell engraftment.
    Stem Cells. 1998;16(3):166-77 PMID: 9617892
  2. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis.
    Surg Oncol Clin N Am. 2001 Apr;10(2):257-69, vii-viiii PMID: 11382586
  3. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.
    Blood. 2002 Nov 1;100(9):3175-82 PMID: 12384415
  4. Natural killer cells in breast cancer cell growth and metastasis in SCID mice.
    Biomed Pharmacother. 2005 Oct;59 Suppl 2:S375-9 PMID: 16507413
  5. Human melanoma metastasis in NSG mice correlates with clinical outcome in patients.
    Sci Transl Med. 2012 Nov 7;4(159):159ra149 PMID: 23136044
  6. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions.
    Nat Rev Cancer. 2008 Oct;8(10):755-68 PMID: 18784658
  7. Epithelial-mesenchymal transitions in tumour progression.
    Nat Rev Cancer. 2002 Jun;2(6):442-54 PMID: 12189386
  8. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
    Clin Cancer Res. 2009 Aug 1;15(15):4867-74 PMID: 19622578
  9. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Mol Cancer Ther. 2010 Apr;9(4):996-1006 PMID: 20371722
  10. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
    Adv Immunol. 2006;90:1-50 PMID: 16730260
  11. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice.
    Int J Oncol. 2007 Oct;31(4):741-51 PMID: 17786304
  12. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Cancer Res. 2006 Apr 1;66(7):3386-91 PMID: 16585158
  13. Efficient tumour formation by single human melanoma cells.
    Nature. 2008 Dec 4;456(7222):593-8 PMID: 19052619
  14. Higher susceptibility of NOG mice to xenotransplanted tumors.
    J Toxicol Sci. 2009 Feb;34(1):123-7 PMID: 19182442
  15. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
    Cancer Cell. 2009 Mar 3;15(3):232-9 PMID: 19249681
  16. Mouse models of advanced spontaneous metastasis for experimental therapeutics.
    Nat Rev Cancer. 2011 Feb;11(2):135-41 PMID: 21258397
  17. A cytokine-mediated link between innate immunity, inflammation, and cancer.
    J Clin Invest. 2007 May;117(5):1175-83 PMID: 17476347
  18. [Immunological aspects of anticancer chemotherapy].
    Bull Acad Natl Med. 2008 Oct;192(7):1469-87; discussion 1487-9 PMID: 19445369
  19. Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo.
    Breast Cancer Res Treat. 2007 Sep;104(3):267-75 PMID: 17066321
  20. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
    Cancer Res. 2008 Jun 15;68(12):4500-5 PMID: 18559492
  21. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
    Clin Cancer Res. 2009 May 15;15(10):3277-86 PMID: 19447870
  22. Microenvironmental regulation of metastasis.
    Nat Rev Cancer. 2009 Apr;9(4):239-52 PMID: 19279573
  23. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
    Nature. 2005 Dec 8;438(7069):820-7 PMID: 16341007
  24. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.
    Nat Med. 1995 Feb;1(2):149-53 PMID: 7585012
  25. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects.
    Leukemia. 1998 Dec;12(12):2029-33 PMID: 9844934
  26. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.
    Gut. 2013 Feb;62(2):259-71 PMID: 22543158
  27. A new mouse model for the study of human breast cancer metastasis.
    PLoS One. 2012;7(10):e47995 PMID: 23118918
  28. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain.
    Immunity. 1995 Mar;2(3):223-38 PMID: 7697543
  29. S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model.
    Oncol Rep. 2005 Sep;14(3):633-7 PMID: 16077966
  30. Paradoxical roles of the immune system during cancer development.
    Nat Rev Cancer. 2006 Jan;6(1):24-37 PMID: 16397525
  31. The influence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro.
    Photochem Photobiol Sci. 2008 Jun;7(6):675-80 PMID: 18528551
  32. Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice.
    Int J Oncol. 2008 Jan;32(1):153-9 PMID: 18097554
  33. Dissemination and growth of cancer cells in metastatic sites.
    Nat Rev Cancer. 2002 Aug;2(8):563-72 PMID: 12154349
  34. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.
    Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S134-9 PMID: 14508091
  35. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.
    Clin Cancer Res. 2009 Oct 15;15(20):6358-66 PMID: 19825954
  36. Immune surveillance of tumors.
    J Clin Invest. 2007 May;117(5):1137-46 PMID: 17476343
  37. Mechanisms of malignant progression.
    Carcinogenesis. 2008 Jun;29(6):1092-5 PMID: 18453542
  38. Immune therapy for cancer.
    Annu Rev Immunol. 2009;27:83-117 PMID: 19007331
  39. Immunity, inflammation, and cancer.
    Cell. 2010 Mar 19;140(6):883-99 PMID: 20303878
  40. The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging.
    Luminescence. 2007 May-Jun;22(3):221-8 PMID: 17286245
  41. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis.
    Cancer Res. 2008 Dec 15;68(24):10068-76 PMID: 19074872
  42. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
    Cancer Metastasis Rev. 2007 Dec;26(3-4):737-47 PMID: 17846863
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2013-00-00
Epub
2013-00-14
Pages
e71270
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC3743873
Subset
IM
Grants
NCI NIH HHS · R01 CA041233 · United States
NCI NIH HHS · CA-41233 · United States
CIHR · 5815 · Canada
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com